ESTRO 2025 - Abstract Book

S1496

Clinical – Mixed sites & palliation

ESTRO 2025

VAS before LDRT was ≥ 6 in 92% of patients, however, with a median follow -up of 6 years (0-10 years), 50% of patients showed an improvement of more than 5 points, achieving VAS 0-1 in 28% of the patients. After 2, 3, 4 and 6 years, 80%, 78%, 75% and 68% of patients maintained response, respectively. Fasciitis was the disorder with best

results, having almost 100% of patients a long-term improvement of the pain after LDRT. In 161 cases, a second course was needed, attaining improvement of pain in 148 of them. Analgesia after treatment was not so necessary in 40% of the patients treated. No toxicities were exposed.

Conclusion: LD-RT is a feasible and secure treatment for musculoskeletal diseases, having better results in inflammatory than degenerative conditions. Two thirds of the patients maintain a long-term response and almost 50% take less medication.

Keywords: low-dose radiotherapy, musculoskeletal, pain

References:

1. R. Mücke, et al. GUIDELINES IN RADIOTHERAPY Radiotherapy for benign diseases Specialist group-specific evidence-based S2e guideline of the German Society for Radiation Oncology (DEGRO) Version 3.0 from 19.11.2022. “Radiotherapy of Benign Diseases”. 2. Micke O, Ugrak E, Bartmann S, et al. Radiotherapy for calcaneodynia, achillodynia, painful gonarthrosis, bursitis trochanterica, and painful shoulder syndrome - Early and late results of a prospective clinical quality assessment. Radiation Oncology (London, England). 2018;13:71. 3.Alvarez B, Montero A, et al. Radiotherapy CT-based contouring atlas for non-malignant skeletal and soft tissue disorders: a practical proposal from Spanish experience. Br J Radiol. 2021 Aug 1;94(1124):20200809.